Nektar Therapeutics (NKTR) Tops Q3 EPS by 1c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $73.61 -3.25%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.1 million versus the consensus estimate of $21.26 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
- UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
